Herceptin

(Trastuzumab)

ApprovedMonoclonal antibody

Trastuzumab is used to treat certain types of breast cancer and stomach cancer that have a specific protein called HER2 on their surface. It works by targeting and attacking cancer cells that have this protein, helping to slow or stop their growth.[2] Herceptin is currently approved and in use across 93 indications[4].[1]

Herceptin is one of 1106 monoclonal antibody programs targeting Non-Small Cell Lung Cancer. It is currently in Approved.

Indications

949

Total Trials

Active Trials

1,105

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Non-Small Cell Lung CancerRecruiting

Colorectal CancerCompleted

Lung CancerWithdrawn

Urothelial CarcinomaUnknown status

Endometrial CancerRecruiting

Breast CancerCompleted

Metastatic Colorectal CancerNot yet recruiting

Metastatic Breast CancerActive, not recruiting

ImmunotherapyUnknown status

Solid TumorsTerminated

Non-Small Cell Lung CancerPhase 2

Recruiting

Colorectal CancerPhase 2

Completed

Lung CancerPhase 2

Withdrawn

Urothelial CarcinomaPhase 2

Unknown status

Endometrial CancerPhase 2

Recruiting

Breast CancerApproved

Completed

Metastatic Colorectal CancerPhase 2

Not yet recruiting

Metastatic Breast CancerPhase 3

Active, not recruiting

ImmunotherapyPhase 2

Unknown status

Solid TumorsPhase 2

Terminated

Showing 10 of 93 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Herceptin

Adenocard

2 3

Zolymbus

AbbVie

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Acupan

YYonsei University

Preclinical

1 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Paracetamol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Gastric Cancer

NCT06085755

Phase 2/3Active, not recruiting

Breast Cancer

NCT04290793

Phase 2Not yet recruiting

Adjuvant Treatment

NCT06439550

Phase 2Recruiting

Neoadjuvant Immunotherapy

NCT05515796

Phase 2Recruiting

Neoadjuvant Treatment

NCT07335081

Q3 2027

Phase 3Active, not recruiting

Breast Cancer

NCT04193059

Clinical

Trials by Indication[1]

Breast Cancer137 trials

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00301899·37 enrolled

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Unknown status·—·Phase 2·NCT04197687·480 enrolled

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

Completed·IInstitut Curie·Phase 1/2·NCT01373710·34 enrolled

Show 134 more trials

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Completed· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT04629846·517 enrolled

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Terminated·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04066790·12 enrolled

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT05838066·880 enrolled

A Study for the Adjuvant Treatment of Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420467·2,413 enrolled

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT02675231·237 enrolled

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00820872·30 enrolled

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00266110·17 enrolled

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Completed· Roche logo

Roche·Phase 2·NCT02536339·40 enrolled

Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309556·536 enrolled

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT05041842·53 enrolled

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00803556·29 enrolled

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00847171·20 enrolled

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Completed·UUniversity of California, San Francisco·Phase 2·NCT03094052·11 enrolled

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01875666·26 enrolled

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Completed·UUniversity of Washington·Phase 1/2·NCT01922921·31 enrolled

Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00004013·60 enrolled

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT00242203·120 enrolled

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Completed· Roche logo

Roche·Phase 4·NCT02419742·110 enrolled

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Terminated·KKimberly Blackwell·Phase 1·NCT02598427·1 enrolled

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Completed· Roche logo

Roche·Phase 3·NCT00448279·58 enrolled

A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

Completed· Roche logo

Roche·Phase 3·NCT01810393·114 enrolled

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Completed·GGBG Forschungs GmbH·Phase 3·NCT02125344·961 enrolled

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

Completed· Roche logo

Roche··NCT00833963·20 enrolled

Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

Completed·BBhuvaneswari Ramaswamy·Phase 2·NCT00428922·26 enrolled

A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

Completed·CCancer Trials Ireland·Phase 3·NCT01526369·75 enrolled

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

Terminated·NNYU Langone Health·Phase 1/2·NCT02297230·44 enrolled

An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Terminated· Roche logo

Roche··NCT01187381·250 enrolled

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00826267·29 enrolled

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

Withdrawn·NNational Cancer Institute, Naples·Phase 2·NCT00434031

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

Terminated·SSpanish Breast Cancer Research Group·Phase 2·NCT00130507·14 enrolled

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Completed·SSOLTI Breast Cancer Research Group·Phase 2·NCT02448420·73 enrolled

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01572038·1,436 enrolled

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

Completed· Roche logo

Roche·Phase 3·NCT01926886·102 enrolled

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00140140·16 enrolled

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Completed· GSK logo

GSK·Phase 2·NCT00524303·100 enrolled

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

Completed· Roche logo

Roche·Phase 2·NCT00005635

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00736970·34 enrolled

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Unknown status·IInstituto Nacional de Cancerologia, Columbia·Phase 2·NCT00533936·160 enrolled

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·N/A·NCT03756064·100 enrolled

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Completed·RRawalpindi Medical College··NCT05931042·1,209 enrolled

Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193076·96 enrolled

Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00006104·46 enrolled

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT01160211·369 enrolled

Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00003612·92 enrolled

Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy

Completed·GGBG Forschungs GmbH·Phase 2·NCT01594177·65 enrolled

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00971737·63 enrolled

Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer

Completed·VVejle Hospital·Phase 2·NCT01242449·10 enrolled

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02139358·15 enrolled

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

Completed·SSOLTI Breast Cancer Research Group·Phase 1·NCT04253561·17 enrolled

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Completed·—·Phase 1·NCT03364348·18 enrolled

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT03523585·608 enrolled

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00876395·719 enrolled

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Unknown status·NNSABP Foundation Inc·Phase 3·NCT00486668·529 enrolled

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Unknown status·AAzienda Ospedaliero-Universitaria di Modena·Phase 3·NCT00629278·2,500 enrolled

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00039455·50 enrolled

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Active, not recruiting·HHebei Medical University Fourth Hospital·Phase 2/3·NCT04290793·113 enrolled

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Terminated·MMayo Clinic·Phase 1·NCT03432741·17 enrolled

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Active, not recruiting·FFudan University·Phase 3·NCT04193059·1,560 enrolled

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Completed·—·Phase 2·NCT00542451·406 enrolled

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Completed· Novartis logo

Novartis·Phase 1·NCT00367471·31 enrolled

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

Unknown status·FFudan University·Phase 2·NCT05076695·37 enrolled

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

Completed·ZZhejiang Hisun Pharmaceutical Co. Ltd.·Phase 3·NCT06107790·570 enrolled

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Unknown status·SShanghai Pudong Hospital·N/A·NCT05656079·204 enrolled

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Terminated·WWest German Study Group·Phase 2·NCT01891357·64 enrolled

Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00429299·121 enrolled

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Active, not recruiting·UUS Oncology Research·Phase 1/2·NCT03379428·34 enrolled

De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer

Active, not recruiting·NNational Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT07421141·186 enrolled

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006228·37 enrolled

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Terminated·—·Phase 2·NCT01185509·31 enrolled

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Suspended·VVeana Therapeutics·Phase 1·NCT04120246·24 enrolled

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00146042·22 enrolled

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT01512199·29 enrolled

A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT01565083·213 enrolled

Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer

Unknown status·ZZhimin Shao·Phase 2·NCT01428414·100 enrolled

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01300962·47 enrolled

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT06435429·550 enrolled

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

Terminated·—·Phase 2·NCT02598310·30 enrolled

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Terminated·IInfinity Pharmaceuticals, Inc.·Phase 2·NCT00817362·29 enrolled

Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer

Withdrawn· GSK logo

GSK·Phase 2·NCT01205217

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00258960·49 enrolled

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Completed· GSK logo

GSK·Phase 3·NCT00320385·296 enrolled

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

Completed·UUniversity of California, San Francisco·Phase 2·NCT00303992·9 enrolled

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Unknown status·PPeking Union Medical College·Phase 1/2·NCT03994107·40 enrolled

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT02605915·98 enrolled

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Completed·WWest German Study Group·Phase 2·NCT03988036·46 enrolled

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00446030·127 enrolled

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

Unknown status·MMidwestern Regional Medical Center·Phase 2·NCT02689921·7 enrolled

Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery

Terminated·UUNICANCER·Phase 2·NCT00674414·82 enrolled

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Completed· Roche logo

Roche·Phase 3·NCT02586025·329 enrolled

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Terminated·OOncolytics Biotech·Phase 1·NCT04102618·26 enrolled

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Not yet recruiting·—·Phase 2·NCT05983094·181 enrolled

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT05720026·560 enrolled

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT01007942·569 enrolled

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00629499·63 enrolled

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT01196052·153 enrolled

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT03199885·190 enrolled

Trastuzumab in Treating Women With Metastatic Breast Cancer

Completed·CCentre Antoine Lacassagne·N/A·NCT00896376·49 enrolled

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

Completed·KKari Kendra·Phase 2·NCT00201760·10 enrolled

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Completed·CCanadian Cancer Trials Group·Phase 1·NCT02649686·15 enrolled

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

Active, not recruiting·UUniversity of Washington··NCT03738553·13 enrolled

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT02614794·612 enrolled

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Not yet recruiting·FFudan University·Phase 2·NCT07150208·140 enrolled

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00679211·110 enrolled

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT01875367·166 enrolled

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Not yet recruiting·FFudan University·Phase 2·NCT07179939·288 enrolled

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Completed·—·Phase 2·NCT01847001·10 enrolled

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Completed· Roche logo

Roche·Phase 4·NCT01301729·32 enrolled

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Completed·YYale University·Phase 2·NCT01855828·50 enrolled

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00004888·84 enrolled

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT05189067·190 enrolled

Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT00427427·75 enrolled

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01434303·37 enrolled

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

Completed·AAccelerated Community Oncology Research Network·Phase 2·NCT00270894·30 enrolled

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Terminated·—·Phase 2·NCT01912963·32 enrolled

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

Recruiting·Wwang shusen·Phase 2·NCT05978648·116 enrolled

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 3·NCT00047255·263 enrolled

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Unknown status·FFuzhou General Hospital·Phase 2·NCT04088110·77 enrolled

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

Recruiting·—·Phase 2·NCT04993014·80 enrolled

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06278870·312 enrolled

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00024154·132 enrolled

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT00788931·15 enrolled

Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery

Completed·UUniversity of Nebraska·Phase 2·NCT01106898·112 enrolled

Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients

Completed·—·Phase 2·NCT00429247·75 enrolled

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Unknown status·AAssociation Tunisienne de lutte Contre le Cancer·Phase 1·NCT01880385·30 enrolled

Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer

Withdrawn·IInstituto do Cancer do Estado de São Paulo·N/A·NCT02102438

RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

Not yet recruiting·FFudan University·Phase 2/3·NCT07366840·268 enrolled

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 3·NCT02947685·518 enrolled

A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

Completed·RR-Pharm·Phase 2·NCT00490646·50 enrolled

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Terminated·—·N/A·NCT01897441·31 enrolled

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT00464646·105 enrolled

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Terminated·VVall d'Hebron Institute of Oncology·Phase 1·NCT05385705·2 enrolled

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT01008150·141 enrolled

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01305941·32 enrolled

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

Completed·YYale University·Phase 2·NCT00411788·11 enrolled

Gastric Cancer14 trials

A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer

Completed· Roche logo

Roche··NCT01839500·1,600 enrolled

Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

Terminated·—·Phase 2·NCT04168931·5 enrolled

Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive

Completed·FFundación para el Progreso de la Oncología en Cantabria·Phase 2·NCT01503983·45 enrolled

Show 11 more trials

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

Active, not recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 2·NCT04908813·150 enrolled

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT07332533·490 enrolled

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02004769·67 enrolled

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT01602406·64 enrolled

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Completed· Roche logo

Roche·Phase 2·NCT01461057·30 enrolled

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Recruiting·JJeeyun Lee·Phase 1/2·NCT06085755·61 enrolled

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT04014075·79 enrolled

Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

Withdrawn·KKorean South West Oncology Group·Phase 2·NCT03766607

T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy

Unknown status·—·Phase 2·NCT02250209·40 enrolled

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Completed·—·Phase 2·NCT01191697·37 enrolled

ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Completed· Roche logo

Roche·Phase 3·NCT01041404·584 enrolled

Metastatic Colorectal Cancer3 trials

Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00006015·26 enrolled

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Not yet recruiting·SSuzhou Teligene Ltd.·Phase 2·NCT06589830·80 enrolled

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Unknown status·NNSABP Foundation Inc·Phase 2·NCT03457896·35 enrolled

HER2 Positive3 trials

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Terminated·MMerrimack Pharmaceuticals·Phase 2·NCT01774851·84 enrolled

A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

Completed· Roche logo

Roche·Phase 3·NCT02040935·128 enrolled

Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer

Completed·OOdense University Hospital·N/A·NCT01295086·27 enrolled

Neoadjuvant2 trials

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Completed·TThe Methodist Hospital Research Institute·Phase 2·NCT02073487·32 enrolled

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Completed· Novartis logo

Novartis·Phase 3·NCT00553358·455 enrolled

40 more indications

Advanced Cancer2 trials

RP-6306 in Patients With Advanced Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT05605509·28 enrolled

Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02318901·16 enrolled

Adjuvant Treatment1 trial

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06439550·42 enrolled

Solid Tumor Malignancies1 trial

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting·EEffector Therapeutics·Phase 1/2·NCT04092673·30 enrolled

Patients With Solid Tumors1 trial

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00028535·18 enrolled

Cancer1 trial

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01649271·13 enrolled

Rectal Cancer1 trial

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05672524·37 enrolled

ESS1 trial

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT01479179

Neoadjuvant Immunotherapy1 trial

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Recruiting·—·Phase 2·NCT05515796·200 enrolled

Refractory1 trial

Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Unknown status·CConsorzio Oncotech·Phase 2·NCT02238509·154 enrolled

Esophageal Adenocarcinoma1 trial

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Completed·AAshwin Somasundaram·Phase 2·NCT03783936·18 enrolled

Recurrent or Metastatic1 trial

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT00084513·18 enrolled

Adult1 trial

Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

Completed·MMeiji Seika Pharma Co., Ltd.·Phase 1·NCT02100917·70 enrolled

Chemotherapy1 trial

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Completed·MMacroGenics·Phase 2/3·NCT04082364·82 enrolled

HER2 Amplification1 trial

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting·CCancer Research UK·Phase 2/3·NCT05786716·30 enrolled

Solid Tumors1 trial

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Terminated·PPuma Biotechnology, Inc.·Phase 2·NCT01953926·582 enrolled

Postmenopausal Women1 trial

Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women

Unknown status·GGangnam Severance Hospital·Phase 2·NCT02214004·132 enrolled

Apatinib1 trial

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Terminated· Novartis logo

Novartis·Phase 3·NCT00968968·37 enrolled

Breast1 trial

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Completed·—·Phase 1·NCT01921335·41 enrolled

Leptomeningeal Disease1 trial

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT04588545·39 enrolled

Efficacy1 trial

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Withdrawn·NNKGen Biotech, Inc.·Phase 1/2·NCT04464967

Biliary Cancer1 trial

Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting·UUNICANCER·Phase 3·NCT05615818·800 enrolled

Neoadjuvant Treatment1 trial

ctDNA in HER2+ EBC Neoadjuvant Treatment

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT07335081·60 enrolled

Advanced/Metastatic Solid Tumors1 trial

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting·DDualityBio Inc.·Phase 1/2·NCT05785741·1,000 enrolled

Colorectal Cancer1 trial

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Completed·SSWOG Cancer Research Network·Phase 2·NCT03365882·240 enrolled

Abemaciclib1 trial

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Withdrawn·—·Phase 1·NCT03846583

Completed·—·Phase 2·NCT00004163·14 enrolled

Immunotherapy1 trial

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Unknown status·FFondazione per la Medicina Personalizzata·Phase 2·NCT04591431·400 enrolled

Advanced Solid Tumors1 trial

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 2·NCT02091141·673 enrolled

Multiple Myeloma1 trial

Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma

Completed·AAEterna Zentaris·N/A·NCT00847366·10 enrolled

Treatment1 trial

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Completed· Novartis logo

Novartis·Phase 3·NCT00490139·8,381 enrolled

Advanced Urothelial Cancer1 trial

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00151034·33 enrolled

Ptosis1 trial

"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

Completed·FFondazione Michelangelo·Phase 2·NCT02530424·102 enrolled

Biliary Tract Cancer1 trial

Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients

Recruiting·TTata Memorial Centre·Phase 3·NCT07062263·220 enrolled

Osteosarcoma1 trial

Trastuzumab in Treating Patients With Recurrent Osteosarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00005033

Gastric Adenocarcinoma1 trial

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Unknown status·AAiping Zhou·Phase 2·NCT05218148·44 enrolled

Paclitaxel1 trial

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Completed·JJapan Breast Cancer Research Group·Phase 3·NCT03264547·446 enrolled

Bevacizumab1 trial

Bevacizumab in Multiple Phase I Combinations

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543504·343 enrolled

Lung Cancer1 trial

GRN1005 for Brain Metastases From Breast or Lung Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01679743

Regulatory

FDA Approval Timeline[5]

Sep 25, 1998

Herceptin

BLA 103792

Sep 25, 1998

HERCEPTIN

BLA BLA103792

Dec 14, 2018

HERZUMA

BLA BLA761091

Jan 18, 2019

ONTRUZANT

BLA BLA761100

Sources

References

[1]
ClinicalTrials.gov — 949 trial records for Trastuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Herceptin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Trastuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Trastuzumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761100). U.S. Food & Drug Administration.
[6]
PubMed — 3 publications indexed for Trastuzumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Organon and Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: HER2 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: OOrganon and Co

Key Publications[6]

Subcutaneous Trastuzumab in HER2-Positive Gastric Cancer: Phase 3 Results

Lancet OncolFeb 27, 2023DOI: 10.1016/S1470-2045(23)00025-1

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: DESTINY-Breast04

N Engl J MedFeb 3, 2022DOI: 10.1056/NEJMoa2115022

Trastuzumab Plus Pertuzumab in Early HER2-Positive Breast Cancer

N Engl J MedMay 24, 2021DOI: 10.1056/NEJMoa2101671

Herceptin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Breast Cancer137 trials

Gastric Cancer14 trials

Metastatic Colorectal Cancer3 trials

HER2 Positive3 trials

Neoadjuvant2 trials

Advanced Cancer2 trials

Adjuvant Treatment1 trial

Solid Tumor Malignancies1 trial

Patients With Solid Tumors1 trial

Cancer1 trial

Rectal Cancer1 trial

ESS1 trial

Neoadjuvant Immunotherapy1 trial

Refractory1 trial

Esophageal Adenocarcinoma1 trial

Recurrent or Metastatic1 trial

Adult1 trial

Chemotherapy1 trial

HER2 Amplification1 trial

Solid Tumors1 trial

Postmenopausal Women1 trial

Apatinib1 trial

Breast1 trial

Leptomeningeal Disease1 trial

Efficacy1 trial

Biliary Cancer1 trial

Neoadjuvant Treatment1 trial

Advanced/Metastatic Solid Tumors1 trial

Colorectal Cancer1 trial

Abemaciclib1 trial

Prostate Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Salivary Gland Cancer1 trial

Immunotherapy1 trial

Advanced Solid Tumors1 trial

Multiple Myeloma1 trial

Treatment1 trial

Advanced Urothelial Cancer1 trial

Ptosis1 trial

Biliary Tract Cancer1 trial

Osteosarcoma1 trial

Gastric Adenocarcinoma1 trial

Paclitaxel1 trial

Bevacizumab1 trial

Lung Cancer1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Key Publications[6]

Related News